1. Pancreatic Hormones and Insulin Receptor Agonists Hongmei Li Mar. 21th, 2006

2. The bulk of the pancreas is an exocrine gland secreting pancreatic fluid into the duodenum after a meal. Inside the pancreas are millions of clusters of cells called islets of Langerhans. The islets are endocrine tissue containing four types of cells. In order of abundance, they are: beta cells, which secrete insulin and amylin; alpha cells, which secrete glucagon; delta cells, which secrete somatostatin gamma cells, which secrete a polypeptide.

3. Pancreatic Hormones  Insulin  Amylin  Glucagon  Somatostatin  Pancreatic Polypeptide

4. A chain B chain Beta cells have channels in their plasma membrane that serve as glucose detectors. Beta cells secrete insulin in response to a rising level of circulating glucose. Insulin is a small protein consisting of an A chain of 21 amino acids linked by two disulfide (S—S) bridges to a B chain of 30 amino acids.

5. Insulin affects many organs:  It stimulates skeletal muscle fibers.  It stimulates liver cells.  It acts on fat cells  It inhibits production of certain enzyme. In each case, insulin triggers these effects by binding to the insulin receptor. glucose uptake glycogen synthesis protein synthesis amino acids uptake enzyme production glycogen breaking fat synthesis

6. Pancreatic Hormones  Insulin  Amylin  Glucagon  Somatostatin  Pancreatic Polypeptide

7. β  Amylin  Amylin is a peptide of 37 amino acids.  It inhibits the secretion of glucagon;  It slows the emptying of the stomach;  It sends a satiety signal to the brain. All of its actions tend to supplement those of insulin, reducing the level of glucose in the blood.

8. Pancreatic Hormones  Insulin  Amylin  Glucagon  Somatostatin  Pancreatic Polypeptide

9. α Glucagon Glucagon, a polypeptide of 29 amino acids, acts principally on the liver.  It stimulates the conversion of glycogen into glucose.  It stimulates the conversion of fat and protein into intermediate metabolites that are ultimately converted into glucose. Glucagon secretion is stimulated by low levels of glucose in the blood; inhibited by high levels, and inhibited by amylin.

10. Pancreatic Hormones  Insulin  Amylin  Glucagon  Somatostatin  Pancreatic Polypeptide

11. δ  Somatostatin Somatostatin consists of two polypeptides, one of 14 amino acids and the other of 28. They work together to reduce the rate at which food is absorbed in the intestine.

12. Pancreatic Hormones  Insulin  Amylin  Glucagon  Somatostatin  Pancreatic Polypeptide

13. γ Pancreatic Polypeptide by Gamma Cells The gamma cells of the islets secrete a 36- amino-acid pancreatic polypeptide, which reduces appetite.

14. The insulin receptor (IR) is a transmembrane glycoprotein, composed of 2α and 2β domains.. Its intracellular tyrosine kinase domain is activated by binding of insulin, leading to a cascade of signaling events.

15. Who need insulin medicine  Type I (insulin dependent) diabetes patients whose body produces no insulin.  Type 2 diabetes patients that do not always produce enough insulin. Treatment  subcutaneous injection

16. Stage 1 Insulin was extracted from the glands of cows and pigs. (1920s) Stage 2 Convert pig insulin into human insulin by removing the one amino acid that distinguishes them and replacing it with the human version. Insulin drug evolution

17.  Stage 3 Insert the human insulin gene into E. coli and culture the recombinant E.coli to produce insulin (trade name = Humulin ® ). Yeast is also used to produce insulin (trade name = Novolin ® ) (1987). Recombinant DNA technology has also made it possible to manufacture slightly-modified forms of human insulin that work faster (Humalog® and NovoLog®) or slower (Lantus®) than regular human insulin.

18. Types of insulin Regular insulins Insulin analogs Pre-mixed insulin Short peptide mimics

19. Regular insulins:  Human insulin: Humulin® (from E.coli), Novalin® (from yeast)  NPH - neutral protamine Hagedorn (NPH), protamine mixed.  Lente® insulin / Ultralente® insullin- zinc added

20. Types of insulin Regular insulins Insulin analogs Pre-mixed insulin Short peptide mimics

21. Insulin Analogs:  Fatty Acid Acylated insulins  Insulin Lispro (Humalog®) (1996)  Insulin Aspart (NovoLog®) (2000)  Insulin Glargine (Lantus®) (2002)  Insulin Detemir (Levemir®) (Jun.,2005)  Insulin Glulisine (Apidra®) (Jan., 2006)

22. Amino Acid Substitutons A- chain Position B- chain Position Source/ Type A21B3B28B29B30 B31 And B32 HumanAsn ProLysThr AspartAsn Aspartic acid LysThr LisproAsnLysProThr GlulisineAsnLysProGluThr GlargineGlyProLysThrArg DetemirLys Myristic acid rapid-acting long-acting

24. Types of insulin Regular insulins Insulin analogs Pre-mixed insulin Short peptide mimics

25. Types of insulin Regular insulins Insulin analogs Pre-mixed insulin Short peptide mimics

26. Insulin receptors were used as targets to screen surrogate peptides in random peptide phage display libraries. Short surrogate peptides IR

27. Short surrogate peptides H2C-D117: 14 a.a. RP9-S371: 16 a.a. 20E2-D118: 24 a.a.

28. Future Directions for new IR agonists  Increased Stability  Less Variability  High Selective Action  Ultra Rapid Onset  Ultra Long Activity  W/O side effects

29. References  Renuka C. P. et.al (2002) J. Biol. Chem. 277, 22590–4  Zoltan V. AND William C. D. (2001) Pharm. Rev. 52, 1-9  Lauge S. et. Al (2003) PNAS 100, 4435-9  Mark R. B. (1997) J. of Clin. Endoc.& Met. 82, 3-7  Gianni C. (1992) FEBS 307, 66-70  Irl B. H., (2001) Clin. Diabetes 19, 146-7  BRUCE W. B. and POUL S. (2001) Diabetes care 24,69-72  http://www.indstate.edu/thcme/mwking/diabetes.html